{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:42:32Z","timestamp":1770723752502,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"governmental VTR-funding of the hospital district of Southwestern Finland"},{"name":"Finnish Cardiac Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00415-018-09167-y","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:39:39Z","timestamp":1546648779000},"page":"515-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-9054","authenticated-orcid":false,"given":"Jussi O. T.","family":"Sipil\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merja","family":"Soilu-H\u00e4nninen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi","family":"Rautava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ville","family":"Kyt\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"key":"9167_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11908-016-0543-8","volume":"18","author":"D Saylor","year":"2016","unstructured":"Saylor D, Venkatesan A (2016) Progressive multifocal leukoencephalopathy in HIV-uninfected Individuals. Curr Inf Dis Rep 18:33. \n                    https:\/\/doi.org\/10.1007\/s11908-016-0543-8","journal-title":"Curr Inf Dis Rep"},{"key":"9167_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","volume":"17","author":"EO Major","year":"2018","unstructured":"Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17:467\u2013480. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(18)30040-1","journal-title":"Lancet Neurol"},{"key":"9167_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","volume":"14","author":"EML Williamson","year":"2017","unstructured":"Williamson EML, Berger JR (2017) Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 14:961\u2013973. \n                    https:\/\/doi.org\/10.1007\/s13311-017-0570-7","journal-title":"Neurotherapeutics"},{"key":"9167_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","volume":"33","author":"JL Casado","year":"2014","unstructured":"Casado JL, Corral I, Garc\u00eda J, Martinez-San Mill\u00e1n J, Navas E, Moreno A, Moreno S (2014) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33:179\u2013187. \n                    https:\/\/doi.org\/10.1007\/s10096-013-1941-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"9167_CR5","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1212\/WNL.0b013e3181f73600","volume":"75","author":"KL Amend","year":"2010","unstructured":"Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J (2010) Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 75:1326\u20131332. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e3181f73600","journal-title":"Neurology"},{"key":"9167_CR6","doi-asserted-by":"publisher","first-page":"107327481772990","DOI":"10.1177\/1073274817729901","volume":"24","author":"C Bohra","year":"2017","unstructured":"Bohra C, Sokol L, Dalia S (2017) Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control 24:1073274817729901. \n                    https:\/\/doi.org\/10.1177\/1073274817729901","journal-title":"Cancer Control"},{"key":"9167_CR7","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/WNL.0000000000004926","volume":"90","author":"E Iacobaeus","year":"2018","unstructured":"Iacobaeus E, Burkill S, Bahmanyar S, Hakim R, Bystr\u00f6m C, Fored M, Olsson T, Brundin L, Montgomery S (2018) The national incidence of PML in Sweden, 1988\u20132013. Neurology 90:e498\u2013e506. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000004926","journal-title":"Neurology"},{"key":"9167_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1474523","author":"D Adrianzen Herrera","year":"2018","unstructured":"Adrianzen Herrera D, Ayyappan S, Jasra S, Kornblum N, Derman O, Shastri A, Mantzaris I, Verma A, Braunschweig I, Janakiram M (2018) Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant\u2014a case series. Leuk Lymphoma. \n                    https:\/\/doi.org\/10.1080\/10428194.2018.1474523\n                    \n                  \n                           (Epub Jul 3)","journal-title":"Leuk Lymphoma"},{"key":"9167_CR9","doi-asserted-by":"publisher","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","volume":"5","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 5:ofy174. \n                    https:\/\/doi.org\/10.1093\/ofid\/ofy174","journal-title":"Open Forum Infect Dis"},{"key":"9167_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","volume":"88","author":"N Schwab","year":"2017","unstructured":"Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88:1197\u20131205. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000003739","journal-title":"Neurology"},{"key":"9167_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","volume":"8","author":"J Borchardt","year":"2016","unstructured":"Borchardt J, Berger JR (2016) Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler Relat Disord 8:145\u2013150. \n                    https:\/\/doi.org\/10.1016\/j.msard.2016.03.005","journal-title":"Mult Scler Relat Disord"},{"key":"9167_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jns.2017.03.001","volume":"376","author":"C Heesen","year":"2017","unstructured":"Heesen C, Kleiter I, Meuth SG, Kr\u00e4mer J, Kasper J, K\u00f6pke S, Gaissmaier W (2017) Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients. J Neurol Sci 376:181\u2013190. \n                    https:\/\/doi.org\/10.1016\/j.jns.2017.03.001","journal-title":"J Neurol Sci"},{"key":"9167_CR13","doi-asserted-by":"publisher","first-page":"e0174858","DOI":"10.1371\/journal.pone.0174858","volume":"12","author":"J Kr\u00e4mer","year":"2017","unstructured":"Kr\u00e4mer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG (2017) Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? PLoS One 12:e0174858. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0174858","journal-title":"PLoS One"},{"key":"9167_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/07853890.2018.1461919","volume":"50","author":"AL Pirttisalo","year":"2018","unstructured":"Pirttisalo AL, Sipil\u00e4 JOT, Soilu-H\u00e4nninen M, Rautava P, Kyt\u00f6 V (2018) Adult hospital admissions associated with multiple sclerosis in Finland in 2004\u20132014. Ann Med 50:354\u2013360. \n                    https:\/\/doi.org\/10.1080\/07853890.2018.1461919","journal-title":"Ann Med"},{"key":"9167_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan A, Madle GC, Seaman HE, de Vries CS (2009) The epidemiology of Guillain\u2013Barr\u00e9 syndrome worldwide. A systematic literature review. Neuroepidemiology 32:150\u2013163. \n                    https:\/\/doi.org\/10.1159\/000184748","journal-title":"Neuroepidemiology"},{"key":"9167_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/bmt.2016.20","volume":"51","author":"JR Passweg","year":"2016","unstructured":"Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF et al (2016) Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 51:786\u2013792. \n                    https:\/\/doi.org\/10.1038\/bmt.2016.20","journal-title":"Bone Marrow Transplant"},{"key":"9167_CR17","first-page":"765","volume":"129","author":"M Soilu-H\u00e4nninen","year":"2013","unstructured":"Soilu-H\u00e4nninen M, P\u00e4iv\u00e4rinta M, Sonninen P, Parkkola R, Vuorinen T, Er\u00e4linna JP (2013) Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy. Duodecim 129:765\u2013770","journal-title":"Duodecim"},{"key":"9167_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87:117\u2013125. \n                    https:\/\/doi.org\/10.1136\/jnnp-2015-311100","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9167_CR19","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","volume":"90","author":"JR Berger","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M (2018) Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90:e1815\u2013e1821. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000005529","journal-title":"Neurology"},{"key":"9167_CR20","doi-asserted-by":"publisher","first-page":"e20967","DOI":"10.1371\/journal.pone.0020967","volume":"6","author":"J Gasnault","year":"2011","unstructured":"Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y, ANRS 125 Trial Team (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0020967","journal-title":"PLoS One"},{"key":"9167_CR21","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.bbmt.2015.11.505","volume":"22","author":"AKA Raajasekar","year":"2016","unstructured":"Raajasekar AKA, Ayyapan S, Khan H, Mantzaris I, Janakiram M (2016) Progressive multifocal leukoencephalopathy associated with hematopoietic stem cell transplant (HSCT) has better prognosis than PML associated with monoclonal antibodies or chemotherapy in hematological malignancies: analysis of a case series. Biol Blood Marrow Transplant 22:S153\u2013S154","journal-title":"Biol Blood Marrow Transplant"},{"key":"9167_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R (2012) Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health 40:505\u2013515. \n                    https:\/\/doi.org\/10.1177\/1403494812456637","journal-title":"Scand J Public Health"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-09167-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-09167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-09167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T19:08:51Z","timestamp":1578164931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-09167-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["9167"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-09167-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jussi O. T. Sipil\u00e4: has received travel grants and congress fee covering (Orion Corporation, Abbvie, Lundbeck, Merck Serono, Sanquin) and holds shares (Orion Corporation). Merja Soilu-H\u00e4nninen: has received congress fee covering, investigator fees and honoraria for lectures or advisory boards (Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva). P\u00e4ivi Rautava: has received congress fee covering (Roche, The Finnish Innovation Fund Sitra). Ville Kyt\u00f6: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Turku University Hospital Clinical Research Center (Turku CRC), THL (permissions no.: THL\/143\/5.05.00\/2015 and THL\/1349\/5.05.00\/2015) and Statistics Finland (TK53-1410-15). Ethics committee appraisal was not stipulated since the study did not include any actual contact with patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}